Avoid common mistakes on your manuscript.
To the Editor: Alternating hemiplegia of childhood 2 (AHC2), caused by pathogenic variants of ATP1A3, is characterized by recurrent episodes of hemiplegia, seizures and tonic-dystonic episodes [1]. Here, we report the use of flunarizine to manage recurrent status epilepticus in an 11-y-old boy patient with AHC2.
He was vaginally delivered at 40 wk of gestation and showed developmental delay from the age of 4 mo. Since then, he has experienced intractable recurrent status epilepticus and left- or right-sided weakness. Brain magnetic resonance imaging (MRI) and electroencephalography (EEG) findings were unremarkable. He experienced focal seizures daily and, on average, developed status epilepticus once a month, requiring repeated hospitalization. When he was 7-y-old, whole exome sequencing revealed a heterozygous de novo pathogenic variant, c.2443G>A (p. Glu815Lys) in the ATP1A3 gene (NM_152296.5), diagnosed with AHC2. On follow-up, the patient showed diffuse brain atrophy and bilateral hippocampal volume reduction on MRI, and right-side-dominant multifocal sharp-wave discharge on EEG. Based on genetic test results, we initiated flunarizine at 5 mg/d and slowly increased the dose to 20 mg/d. Since its administration, the patient has shown no status epilepticus, and the frequency of focal seizures and acute dystonia have decreased by more than 50%.
Showing varying levels of efficacy in different clinical manifestations and genetic variants of AHC2, flunarizine is frequently used in AHC2 treatment [2, 3]. In AHC2, the dysfunction of the Na+/K+ ATPase pump results in increased calcium influx via N-type voltage-gated calcium channels. In addition, pump inactivation leads to increased neuronal calcium levels and causes cell death. Flunarizine, a calcium channel blocker, exerts its therapeutic effects by inhibiting intracellular calcium elevation, is known to be effective for hemiplegic episodes and dystonia in AHC2 [1, 4]. Our case demonstrates that flunarizine can effectively improve recurrent status epilepticus in AHC2, as a targeted treatment for ATP1A3 mutations.
References
Samanta D. Management of alternating hemiplegia of childhood: a review. Pediatr Neurol. 2020;103:12–20.
Kasinathan A, Sharawat IK, Sahu JK, Sankhyan N. Topiramate therapy in alternating hemiplegia of childhood. Indian J Pediatr. 2017;84:957–8.
Cordani R, Stagnaro M, Pisciotta L, et al. Alternating hemiplegia of childhood: genotype-phenotype correlations in a cohort of 39 Italian patients. Front Neurol. 2021;12:658451.
Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and treatment of alternating hemiplegia of childhood. Curr Treat Options Neurol. 2017;19:8.
Acknowledgements
The authors are grateful to all staff members, doctors, and statistical consultants involved in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, H., Na, JH., Lee, H. et al. Effect of Flunarizine on Recurrent Status Epilepticus in a Patient with Alternating Hemiplegia of Childhood. Indian J Pediatr 91, 197 (2024). https://doi.org/10.1007/s12098-023-04832-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-023-04832-1